WMJ : official publication of the State Medical Society of Wisconsin
Cure8 research brief
Why This Matters
This case report suggests risankizumab (an IL‑23 inhibitor) resolved a stubborn cutaneous Crohn’s lesion that persisted despite anti‑TNF therapy, which could matter for patients with similar treatment‑resistant skin manifestations.
Who Should Pay Attention
Patients with Crohn’s disease and persistent skin manifestations; clinicians treating extraintestinal manifestations; patients on biologics considering a switch for refractory symptoms.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
A published case report describes a 75-year-old man with Crohn’s disease who developed a gluteal fissure consistent with cutaneous Crohn’s while on long-term adalimumab (an anti-TNF). The authors report that switching the patient to risankizumab (an IL‑23 inhibitor) led to resolution of the skin lesion while his intestinal disease remained in remission.
This is presented as the first reported case of anti‑TNF–resistant cutaneous Crohn’s responding to an IL‑23 inhibitor. The article frames IL‑23 blockade as a promising option for extraintestinal skin manifestations, though it notes TNF inhibitors remain standard of care for many EIMs.
Because the source material is an abstract/case report, it provides an individual patient experience rather than comparative trial data. It can generate hypotheses and may inform clinician discussions about alternatives when skin disease is refractory to anti‑TNF therapy, but it does not establish effectiveness for broader patient populations.
Keep In Mind
Single‑patient case report presented at abstract depth; useful for hypothesis generation but not definitive evidence. No broader safety or efficacy conclusions can be drawn from this report.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationWMJ : official publication of the State Medical Society of Wisconsin
AuthorsBrennan K, Stein D, Roth GM
Study typeIm, journal article, case reports
Indexed viaEurope PMC
Source typeResearch paper
PublishedJan 1, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Will Skyrizi & Rinvoq Drive AbbVie's Top-Line Growth in Q3? - TradingView
Patients and clinicians may see continued availability and promotion of Skyrizi and Rinvoq across IBD indications, which can affect prescribing options and market competition. Sales growth and approvals also influence...
VIDEO: Longstanding therapies, recent approvals provide options in Crohn’s disease
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...
AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next - TradingView
This article explains why two widely used IBD drugs from AbbVie (Skyrizi and Rinvoq) are central to the company’s growth and describes ongoing development efforts that could expand treatment options and indications in...